Navigation Links
Thomson Scientific Announces BONDplus for Biological Researchers
Date:9/10/2007

Life Science Platform Delivers Real Time, Comprehensive and Seamless Public and Proprietary Biological Sequence, Interaction and Patent Information

PHILADELPHIA, Sept. 10 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, announced today the release of BONDplus, an integrated, web-based data platform to address the information and analytic needs of biological researchers.

Compiled from 15 assembled resources including GenBank, RefSeq, Entrez Gene and UniProtKB/Swiss-Prot, BONDplus allows researchers to move beyond the genome and leverage publicly available biological sequence data, BINDplus biomolecular interaction data as well as GENESEQ, a value added database of patented biological sequences. The platform allows novel insights into biological research including target-based discovery and rational drug design.

"Today's life science data management faces considerable hurdles due to years of fragmented and non-standardized production of biological data," said Jon Brett-Harris, executive vice president of pharmaceutical and chemical markets at Thomson Scientific. "Since solutions are frequently focused on one data type or in a niche area, an integrated platform can provide a distinct competitive advantage, allowing scientists not only to access public domain data, but also to integrate their own proprietary data and value-added Thomson Scientific data in a consistent and user-friendly format."

BONDplus provides an intuitive and value-added resource for any researcher by uniting the genomic, proteomic and metabolomic research communities around one comprehensive platform. The subscription service provides information from over 15 assembled resources including BINDplus and GENESEQ in addition to pre- computed data sets with BLAST functionality, visualization tools and over 80 million in public domain sequences.

A leading provider of life science research information, Thomson serves primary, secondary and tertiary data types, ranging from proteins and small molecules to gene and protein expression and more complex data types such as toxicology/efficacy data, biomarker, interaction and pathway information.

For more information on BONDplus, please visit: http://scientific.thomson.com/bondplus/

About The Thomson Corporation

The Thomson Corporation (http://www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.


'/>"/>
SOURCE Thomson Scientific
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Scientific markers of aging described
2. A Settlement Over Stem Cell Controversy Through Scientific Research
3. A Scientific Explanation For Out Of Body Experience
4. PUFA Good For Heart: Gets The Scientific Seal
5. Forensic Phonetics – Scientific Solution for Legal Problem
6. Old Indian Advice Has A Scientific Backing Now!
7. India To Highlight Its Scientific Achievements
8. Thumbs up in weight loss for vegetarian diets: scientific review
9. Scientific Research in a War Zone
10. Unscientific Depression Drugs aplenty in Health Stores
11. No Scientific Evidence to Support Drug Safety Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... research and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money ... be packaged with the April edition of American Veterinarian™. , “We ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , ... pursue the recent RNA methylation “gold rush” with their established portfolio of optimized ... characteristics of N6-methyladenosine, or m6A , RNA methylation has received a new ...
(Date:3/27/2017)... Los Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... for men with prostate cancer, including all stages, is more than 95%. Once the ... drops drastically to less than 30%. To find out how to avoid this latter ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... entered a settlement agreement to resolve the pending litigation between itself and 1800 ... the District of Utah). , “I am thrilled to announce that we have ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Harris Communications, ... of hearing, is bringing its latest products to the Deaf Seniors of America Conference, ... have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
(Date:3/27/2017)... , March 27, 2017 ... clinical-stage pharmaceutical company specializing in the development of cannabinoid-based ... offering in the United States ... ADS representing 40 ordinary shares of the Company, ... addition, Therapix has granted the underwriters a 45-day ...
Breaking Medicine Technology: